Archer Daniels Midland (ADM)

Cost of Revenue

$76.46B

TTM · Period ending: · USD

ADM logo

ADM Cost of Revenue

Latest reported$76.46B
ADM TTM Cost of Revenue ($0.00 → $76.46B)
High-resolution chart · PNG

ADM cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Archer Daniels Midland Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
76,459,000,000
75,906,000,000
75,633,000,000
78,430,000,000
77,900,000,000
78,559,000,000
79,752,000,000
80,850,000,000
82,163,000,000
84,618,000,000
86,422,000,000
89,361,000,000
92,348,000,000
94,225,000,000
93,986,000,000
91,249,000,000
87,391,000,000
83,670,000,000
79,262,000,000
74,448,000,000
69,518,000,000
63,228,000,000
59,902,000,000
58,436,000,000
60,000,000,000
60,152,000,000
60,509,000,000
60,243,000,000
59,337,000,000
59,899,000,000
60,160,000,000
60,397,000,000
59,670,000,000
57,834,000,000
57,313,000,000
57,657,000,000
58,384,000,000
59,225,000,000
58,712,000,000
58,817,000,000
59,551,000,000
60,881,000,000
63,682,000,000
67,545,000,000
68,716,000,000
72,816,000,000
76,433,000,000
79,963,000,000
83,553,000,000
84,965,000,000
85,915,000,000
83,944,000,000
85,569,000,000
83,982,000,000
85,504,000,000
85,370,000,000
85,280,000,000
84,050,000,000
81,253,000,000
76,376,000,000
69,381,000,000
64,718,000,000
59,882,000,000
57,839,000,000
59,233,000,000
59,172,000,000
59,773,000,000
65,118,000,000
69,924,000,000
73,282,000,000
73,369,000,000
65,974,000,000
56,493,297,000
49,577,297,000
44,097,297,000
40,780,641,000
38,002,777,000
35,719,886,000
34,167,403,000
33,630,297,000
33,811,223,000
33,368,429,000
33,247,730,000
33,512,471,000
33,795,824,000
34,608,509,000
34,797,901,000
34,003,070,000
32,466,664,000
31,238,846,000
29,971,131,000
28,980,895,000
28,022,967,000
25,327,707,000
22,967,920,000
21,242,194,000
19,537,178,000
19,498,950,000
19,066,933,000
18,619,623,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.